- Home
- ECO vs AGIO Comparison
ECO vs AGIO Comparison
Compare ECO & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECO | AGIO |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2023 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ECO | AGIO |
|---|---|---|
| Price | $50.79 | $28.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $42.00 | $37.63 |
| AVG Volume (30 Days) | 526.4K | ★ 642.1K |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | ★ 7.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $16.07 | $75.68 |
| Revenue Next Year | N/A | $167.63 |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.91 | $22.24 |
| 52 Week High | $57.29 | $46.00 |
Technical Indicators
Market Signals| Indicator | ECO | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.17 | 52.76 |
| Support Level | $22.46 | $26.48 |
| Resistance Level | $57.29 | $29.49 |
| Average True Range (ATR) | 1.82 | 0.92 |
| MACD | -0.21 | -0.02 |
| Stochastic Oscillator | 93.86 | 69.02 |
Price Performance
Historical ComparisonAbout ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.